β-blockers reduce the incidence of cardiac events in post-myocardial infarction patients

Japanese Heart Journal

Volumn 41, Issue 3, 2000, Pages 279-294

  Ishikawa, Kinji ^a   Miyataka, Masaru ^a   Kanamasa, Ken ^a   Hayashi, Takahiro ^a   Takenaka, Toshihiko ^a   Inoki, Tatsu ^a   Katayama, Katsuhiko ^a   Kimura, Akio ^a   Yabushita, Hiroshi ^a   Kitayama, Koji ^a   Taniwa, Takaaki ^a   Nakano, Atsushi ^a  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cardiac event; Secondary prevention of myocardial infarction; Sudden death; blockers

Indexed keywords

ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; AROTINOLOL; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETAXOLOL; BISOPROLOL; CALCIUM ANTAGONIST; CARTEOLOL; CELIPROLOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; METOPROLOL; NADOLOL; NIPRADILOL; NITRATE; PROPRANOLOL; WARFARIN;

ADULT; AGED; ARTICLE; CAUSE OF DEATH; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FOLLOW UP; HEART DISEASE; HEART INFARCTION; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; RECURRENT DISEASE; RETROSPECTIVE STUDY; RISK; SUDDEN DEATH;

EID: 17044450408     PISSN: 00214868     EISSN: None     Source Type: Journal    
DOI: 10.1536/jhj.41.279     Document Type: Article

References (36)

1. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 1985; 27: 335-71.
2. Soriano JB, Hoes AW, Meems L, Grobbee DE. Increased survival with β-blockers: importance of ancillary properties. Prog Cardiovasc Dis 1997; 39: 445-56.
3. Ryan TJ, Anderson JL, Antman EM, et al. ACC/AHA guidelines for the management of patients with acute myocardial infarction: Executive summary. A report of the American College of Cardiology / American Heart Association task force on practice guidelines (Committee on management of acute myocardial infarction). Circulation 1996; 94: 2341-50.
4. Ryan TJ, Antman EM, Brooks NH, et al. 1999 Update: ACC/AHA Guidelines tor the management of patients with acute myocardial infarction: Executive summary and recommendations. A report of the American College of Cardiology / American Heart Association task force on practice guidelines (committee on management of acute myocardial infarction). Circulation 1999; 100: 1016-30.
5. Recommendations of the task force of the European Society of Cardiology. Management of stable angina pectoris. Eur Heart J 1997; 18: 394-413.
6. Wood D. European and American recommendations for coronary heart disease prevention. Eur Heart J 1998; 19(suppl A): A12-9.
7. May GS, Eberlein KA, Furberg CD, Passamani ER, DeMets DL. Secondary prevention after myocardial infarction: a review of long-term trials. Prog Cardiovasc Dis 1982; 24: 331-52.
8. Yusuf S, Sleight P, Held P, McMahon S. Routine medical management of acute myocardial infarction. Lessons from overviews of recent randomized controlled trials. Circulation 1990; 82 (suppl II): II-117-34.
9. Olsson G, Äblad B, Rydén L. Long-term cardiovascular effects of metoprolol therapy: a review article. J Clin Pharmacol 1990; 30: S118-23.
10. Olsson G, Rydén L. Prevention of sudden death using β-blockers. Review of possible contributory actions. Circulation 1991; 84 (suppl VI): VI-33-7.
11. Hjalmarson Å, Olsson G. Myocardial infarction. Effects of β-blockade. Circulation 1991; 84 (suppl VI): VI-101-7.
12. Kendall MJ, Lynch KP, Hjalmarson Å, Kjekshus J. β-blockers and sudden cardiac death. Ann Intern Med 1995; 123: 358-67.
13. Hjalmarson Å. Effects of beta blockade on sudden cardiac death during acute myocardial infarction and the postinfarction period. Am J Cardiol 1997; 80 (9B): 35J-39J.
14. Deedwania PC, Carbajal EV. Role of beta blockade in the treatment of myocardial ischemia. Am J Cardiol 1997; 80 (9B): 23J-28J.
15. Sleight P. Professor Peter Sleight's reflections on the use of β-blocking agents after myocardial infarction. Am Heart J 1997; 134: S15-S20.
16. Ball SG. Beta-blockers and antithrombotics for secondary prevention after myocardial infarction. Eur Heart J 1998; 19: 14-5.
17. Prisltipino C, Finocchiaro ML, Beltrame JF, et al. Differences in coronary vasospastic response after recent myocardial infarction in Japanese and Caucasian patients. Circulation 1997; 96 (suppl I): I-534 (abstract).
18. Lown B, Calvert AF, Armington R, Ryan M. Monitoring for serious arrhythmias and high risk of sudden death. Circulation 1975; 51 (suppl III): III-189-98.
19. Heger JJ, Weyman AE, Wann LS, Rogers EW, Dillon JC, Feigenbaum H. Cross-sectional echocardiographic analysis of the extent of left ventricular asynergy in acute myocardial infarction. Circulation 1980; 61: 1113-8.
20. Snow PJD. Effect of propranolol in myocardial infarction. Lancet 1965; 2: 551-3.
21. The Norwegian Multicenter Study Group. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 1981; 304: 801-7.
22. Hjalmarson Ås, Elmfeldt D, Herlitz J, et al. Effect on mortality of metoprolol in acute myocardial infarction. Lancet 1981; 2: 823-7.
23. β-Blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. JAMA 1982; 247: 1707-14.
24. Krumholz HM, Radford MJ, Wang Y, Chen J, Marciniak TA. Early β-blocker therapy for acute myocardial infarction in elderly patients. Ann Intern Med 1999; 131: 648-54.
25. Krumholz HM, Radford MJ, Wang Y, Chen J, Heiat A, Marciniak TA. National use and effectiveness of β-blockers for the treatment of elderly patients after acute myocardial infarction. National Cooperative Cardiovascular Project. JAMA 1998; 280; 623-9.
26. Soumerai SB, McLaughlin TJ, Spiegelman D, Hertzmark E, Thibault G, Goldman L. Adverse outcomes of underuse of β-blockers in elderly survivors of acute myocardial infarction. JAMA 1997; 277: 115-21.
27. Miyataka M, Kanamasa K, Hayashi T, et al. Prevention of cardiac events by metoprolol in elderly patients after myocardial infarction. Heart 1999; 31: 595-600 (in Japanese).
28. Ishikawa K, Kanamasa K, Hama J, et al. Prevention of cardiac events by β-blocking agents in elderly patients after myocardial infarction. Jpn J Geriat 1997; 34: 273-7 (in Japanese).
29. Viskin S, Barron H. Beta blockers prevent cardiac death following a myocardial infarction: So why are so many infarct survivors discharged without beta blockers? Am J Cardiol 1996; 78: 821-2.
30. Prichard B.N.C. β-adrenoceptor blocking drugs-Classification. Br J clin Pharmac 1978; 5: 379-99.
31. Kendall MJ. Clinical relevance of pharmacokinetic differences between beta blockers. Am J Cardiol 1997; 80(9B): 15J-19J.
32. Kjekshus JK. Importance of heart rate in determining beta-blocker efficacy in acute and long-term acute myocardial infarction intervention trials. Am J Cardiol 1986; 57: 43F-49F.
33. Boissel JP, Leizorovicz A, Picolet H, Peyrieux JC. Secondary prevention after high-risk acute myocardial infarction with low-dose acebutolol. Am J Cardiol 1990; 66: 251-60.
34. Basu S, Senior R, Raval U, van der Does R, Bruckner T, Lahiri A. Beneficial effects of intravenous and oral carvedilol treatment in acute myocardial infarction. A placebo-controlled, randomized trial. Circulation 1997; 96: 183-91.
35. Frishman WH, Lazar EJ. Reduction of mortality, sudden death and non-fatal reinfarction with beta-adrenergic blockers in survivors of acute myocardial infarction: A new hypothesis regarding the cardioprotective action of beta-adrenergic blockade. Am J Cardiol 1990; 66: 66G-70G.
36. Kennedy HL. Beta blockade, ventricular arrhythmias, and sudden cardiac death. Am J Cardiol 1997; 80: 29J-34J.